logo
  • Our Services & Expertise
    • Consulting
      • Consulting Overview
      • Clinical Trial Strategy & Operations
      • Medical Imaging Strategy & Operations
      • Radiopharmaceutical Strategy & Operations
      • Mergers & Acquisitions Advisory
      • Musculoskeletal Services
      • Neuroscience Expertise
      • Fractional C-Suite
      • Consultant Publications
    • Regulatory Affairs
      • FDA Meeting Request Calculator
    • Marketing
    • Data & Analytics
      • Bracken CRM Add-On
      • Bracken CRM Add-On Demos
  • Our Team
  • Our Values
  • Our Media
    • Blog
    • Case Studies
    • Fractals: Our Podcast
    • Infographics
    • The Leaflet: Our Newsletter
    • Resources
    • Events & Conferences
  • Contact Us
  • There are no suggestions because the search field is empty.

Insights & Intel

Life science observations from inside the industry

Explore “Insights & Intel,” the Bracken blog. Our team of life science experts is laser focused on the news and evolution of the industry, from marketing trends to actionable interpretation of the latest regulatory guidances. Discover the latest from Bracken.

Browse Our Media
    Filters
    All
    • ALL
    • Clinical Trials Industry
    • Clinical Trial Intelligence
    • Regulatory
    • Sales & Marketing
    • News
    • Interviews
    • Life Science
    • Medical Imaging
    • Data Analytics
    • Infographics
    • Radiopharmaceutical
    • Advertising
    • Due Diligence
    • Neuroscience
    • Digital Health
    • Drug Development
    • Real World Data
    FDA’s Shift from Animal Testing: Impact on Microdosing and PET Imaging in Radiopharmaceutical Development
    Regulatory Radiopharmaceutical

    featured blog post

    FDA’s Shift from Animal Testing: Impact on Microdosing and PET Imaging in Radiopharmaceutical Development

    Learn More
    Regulatory Radiopharmaceutical
    FDA’s Shift from Animal Testing: Impact on Microdosing and PET Imaging in Radiopharmaceutical Development
    Chelsea Miller, MA & Sandy McEwan, MB, BS, MSc, FRCPC, FSNMMI
    Learn More
    Regulatory
    FDA Launches Commissioner’s National Priority Voucher Program to Accelerate Drug Review
    Bracken
    Learn More
    Regulatory
    Navigating Drug Development Amid FDA Resource Challenges
    Bracken
    Learn More
    Regulatory
    What to Do if Your IND Is Placed on Clinical Hold
    Bracken
    Learn More
    Regulatory
    Keeping Pace with Regulatory Change: Key FDA Updates in Early 2025
    Bracken
    Learn More
    Regulatory
    Optimizing Written and Face-to-Face Communications with the FDA
    Bracken
    Learn More
    Regulatory
    FDA Sunsets Rare Pediatric Disease Program: Critical Updates for 2024
    Bracken
    Learn More
    Regulatory
    The Patient Voice in Cancer Treatment: Unpacking FDA’s Game-Changing Guidelines
    Martin Collyer, MSc, FCCA
    Learn More
    Regulatory
    The Crucial End of Phase 2 FDA Meeting: A Drug Development Milestone
    Bracken
    Learn More
    Regulatory
    Navigating FDA's New Benefit-Risk Assessment Guidance for New Drug and Biological Products
    Martin Collyer, MSc, FCCA
    Learn More
    Regulatory
    A Path Forward: The Journey to Orphan Drug Destination
    Bracken
    Learn More
    Regulatory
    The Path to FDA Approval: When to Consider a Pre-IND Meeting
    Bracken
    Learn More
    1 2 3
    logo

    Contact

    Schedule a Call

    The Bracken Group
    12 Penns Trail
    Newtown, PA 18940

    + 1 215 648 1208
    info@thebrackengroup.com

    Connect

    Subscribe to our Newsletter
    Linkedin
    • Services
      • C-suite
      • Regulatory
      • Marketing
      • Custom Analytics
      • Consulting
    • Solutions
      • Bracken CRM
    • Media
      • Blog
      • Case Studies
      • Resources
      • The Leaflet
      • Instagram
    • Ecosystem
      • Our Team & Story
      • Careers
      • Contact